BG104222A - Novel carboxylic acid derivatives, their production and their use as mixed eta/etb endothelin-receptor antagonists - Google Patents

Novel carboxylic acid derivatives, their production and their use as mixed eta/etb endothelin-receptor antagonists

Info

Publication number
BG104222A
BG104222A BG104222A BG10422200A BG104222A BG 104222 A BG104222 A BG 104222A BG 104222 A BG104222 A BG 104222A BG 10422200 A BG10422200 A BG 10422200A BG 104222 A BG104222 A BG 104222A
Authority
BG
Bulgaria
Prior art keywords
carboxylic acid
receptor antagonists
acid derivatives
production
novel carboxylic
Prior art date
Application number
BG104222A
Other languages
Bulgarian (bg)
English (en)
Inventor
Wilhelm Amberg
Rolf Jansen
Dagmar Klinge
Hartmut Riechers
Stefan Hergenroeder
Manfred Raschack
Liliane Unger
Original Assignee
Basf Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19738578A external-priority patent/DE19738578A1/de
Priority claimed from DE1998111915 external-priority patent/DE19811915A1/de
Application filed by Basf Aktiengesellschaft filed Critical Basf Aktiengesellschaft
Publication of BG104222A publication Critical patent/BG104222A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/36—One oxygen atom
    • C07D263/38—One oxygen atom attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/44—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BG104222A 1997-09-04 2000-03-06 Novel carboxylic acid derivatives, their production and their use as mixed eta/etb endothelin-receptor antagonists BG104222A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19738578A DE19738578A1 (de) 1997-09-04 1997-09-04 Neue Carbonsäurederivate, ihre Herstellung und Verwendung als gemischte ET¶A¶/ET¶B¶-Rezeptorantagonisten
DE1998111915 DE19811915A1 (de) 1998-03-18 1998-03-18 Neue Carbonsäurederivate, ihre Herstellung und Verwendung als gemischte ET¶A¶/ET¶B¶-Rezeptorantagonisten
PCT/EP1998/005354 WO1999011629A1 (fr) 1997-09-04 1998-08-24 Nouveaux derives d'acide carboxylique, leur production et leur utilisation comme antagonistes mixtes des recepteurs d'endotheline eta et et¿b?

Publications (1)

Publication Number Publication Date
BG104222A true BG104222A (en) 2001-02-28

Family

ID=26039663

Family Applications (1)

Application Number Title Priority Date Filing Date
BG104222A BG104222A (en) 1997-09-04 2000-03-06 Novel carboxylic acid derivatives, their production and their use as mixed eta/etb endothelin-receptor antagonists

Country Status (21)

Country Link
EP (1) EP1009741A1 (fr)
JP (1) JP2001514254A (fr)
KR (1) KR20010023615A (fr)
CN (1) CN1269792A (fr)
AR (1) AR017052A1 (fr)
AU (1) AU748610B2 (fr)
BG (1) BG104222A (fr)
BR (1) BR9811631A (fr)
CA (1) CA2302350A1 (fr)
CO (1) CO4970738A1 (fr)
HR (1) HRP980484A2 (fr)
HU (1) HUP0004935A3 (fr)
ID (1) ID25620A (fr)
IL (1) IL134276A0 (fr)
NO (1) NO20001077D0 (fr)
NZ (1) NZ502660A (fr)
PL (1) PL338954A1 (fr)
SK (1) SK1522000A3 (fr)
TR (1) TR200000602T2 (fr)
TW (1) TW546295B (fr)
WO (1) WO1999011629A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19924892A1 (de) * 1999-06-01 2000-12-07 Basf Ag Neue Carbonsäurederivate mit arylsubstituierten Stickstoffheterocyclen, ihre Herstellung und Verwendung als Endothelin Rezeptorantagonisten
AU2007267209A1 (en) * 2006-05-29 2007-12-06 Nicox S.A. Nitrated heterocyclic compounds as endothelin receptor antagonist
AU2009221179A1 (en) 2008-03-05 2009-09-11 Boehringer Ingelheim International Gmbh Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation
ES2462065T3 (es) * 2009-07-10 2014-05-22 Cadila Healthcare Limited Proceso mejorado para la preparación de Ambrisentán e intermedios novedosos de este
AU2011217206A1 (en) 2010-02-19 2012-08-02 Boehringer Ingelheim International Gmbh Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation
EP2760868B1 (fr) 2011-08-17 2018-04-25 Boehringer Ingelheim International GmbH Dérivés de furo[3,4-c]quinoléine, médicaments contenant ces composés, leur utilisation et procédé de leur préparation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4411225A1 (de) * 1994-03-31 1995-10-05 Basf Ag Verwendung von Carbonsäurederivaten als Arzneimittel
DE19533023B4 (de) * 1994-10-14 2007-05-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
WO1997028160A1 (fr) * 1996-02-01 1997-08-07 Smithkline Beecham Corporation Antagonistes des recepteurs de l'endotheline
DE19614542A1 (de) * 1996-04-12 1997-10-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
DE19636046A1 (de) * 1996-09-05 1998-03-12 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung als gemischte ET¶A¶/ET¶B¶-Rezeptorantagonisten

Also Published As

Publication number Publication date
WO1999011629A1 (fr) 1999-03-11
NO20001077L (no) 2000-03-02
CA2302350A1 (fr) 1999-03-11
JP2001514254A (ja) 2001-09-11
AU748610B2 (en) 2002-06-06
AR017052A1 (es) 2001-08-22
HUP0004935A3 (en) 2001-12-28
NZ502660A (en) 2002-02-01
CO4970738A1 (es) 2000-11-07
IL134276A0 (en) 2001-04-30
CN1269792A (zh) 2000-10-11
HUP0004935A2 (hu) 2001-10-28
TR200000602T2 (tr) 2000-12-21
TW546295B (en) 2003-08-11
PL338954A1 (en) 2000-12-04
SK1522000A3 (en) 2000-08-14
NO20001077D0 (no) 2000-03-02
HRP980484A2 (en) 1999-06-30
EP1009741A1 (fr) 2000-06-21
KR20010023615A (ko) 2001-03-26
ID25620A (id) 2000-10-19
AU9533398A (en) 1999-03-22
BR9811631A (pt) 2000-09-26

Similar Documents

Publication Publication Date Title
BG105661A (en) Hydroxy diphenylurea sulfonamides as il-8 receptor antagonists
MX9605450A (es) Tratamiento para ateroesclerosis y otras enfermedades cardiovasculares e inflamatorias.
TR200102800T2 (tr) Yeni bileşikler.
MX9801987A (es) Nuevos derivados de aminoacido, su obtencion y su uso.
SE9702773D0 (sv) Novel compounds
AU4552497A (en) Novel carboxylic acid derivatives, their preparation and use as mixed eta/etb receptor antagonists
MXPA03008811A (es) Procedimiento para la preparacion de 4,6-diaminopirimido (5,4-d) pirimidinas.
PL322001A1 (en) 1-aryl-2-acetylamino ethane compounds, their application as antagonists of neurokinin, in particular of neurokinin 1
MY120550A (en) Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-10-ols, processes for preparing them and their use as pharmaceutical compositions.
TR200001102T2 (tr) İkameli tetrahidropirimidinen türevleri, üretimleri ve kullanımları.
BG104022A (en) New beta-amino and beta-azidocarboxylic acid derivatives, the production thereof and the use thereof as endothelin receptor antagonists
TR200001182T2 (tr) Yeni karbonik asit türevleri, üretimleri ve kullanımları.
TR199901416T2 (xx) Heterosiklik karbonikasit t�revleri.
WO1999037291A3 (fr) Utilisation de sulfonamides substitues comme agents antiviraux et nouvelles substances
IL134276A0 (en) Novel carboxylic acid derivatives, their production and their use as mixed eta/etb endothelin-receptor antagonists
MX9603045A (es) Antagonistas de los receptores endoteliales.
MX9603199A (es) Antagonistas de receptores a endotelina.
ZA983231B (en) Substituted benzyloxyimino compounds.
NZ516209A (en) Indoloazepines as vasopressin receptor antagonists
MX9603087A (es) Procedimiento para la obtencion de aminocarboniltriazolinonas substituidas.
BG106321A (en) Novel carboxylic acid derivatives with 5,6- substituted pyrimidine ring, the production and utilization thereof as endothelin receptor antagonists
IL137038A0 (en) 5-substituted pyrimidine-2-yloxy carboxylic acid derivatives, the production of the same and their utilization as endothelin antagonists
TR200001365T2 (tr) Yeni heterosiklik ikame edilmiş a-hidroksikarbonik asit türevleri
BG106154A (en) Carboxylic acid derivatives comprising aryl-substituted nitrogen heterocycles, methods for their production and their use as endothelin receptor antagonists
BG105618A (en) Beta-amido and beta-sulphonamide derivatives of carboxylic acids, method for preparation and application as endothelin-receptor antagonists